Иные терапевтические подходы в лечении пациентов с глаукомой

    1. Kumar A, Ou Y. From bench to behavior: the role of lifestyle factors on intraocular pressure, neuroprotection, and disease progression in glaucoma. Clin Exp Ophthalmol. 2023;51(4):380-394. doi: 10.1111/ceo.14218

    2. Weinreb RN, Liebmann JM, Cioffi GA, et al. Oral memantine for the treatment of glaucoma: design and results of 2 randomized, placebo-controlled, phase 3 studies. Ophthalmology. 2018;125(12):1874-1885. doi: 10.1016/j.ophtha.2018.06.017

    3. Crowston JG, Kong YXG, Trounce IA, et al. An acute intraocular pressure challenge to assess retinal ganglion cell injury and recovery in the mouse. Exp Eye Res. 2015;141:3-8. doi: 10.1016/j.exer.2015.03.006

    4. Williams PA, Harder JM, John SWM. Glaucoma as a metabolic optic neuropathy: making the case for nicotinamide treatment in glaucoma. J Glaucoma. 2017;26(12):1161-1168. doi: 10.1097/IJG.0000000000000767

    5. Tribble JR, Otmani A, Sun S, et al. Nicotinamide provides neuroprotection in glaucoma by protecting against mitochondrial and metabolic dysfunction. Redox Biol. 2021;43:101988. doi: 10.1016/j.redox.2021.101988

    6. De Moraes CG, John SWM, Williams PA, et al. Nicotinamide and pyruvate for neuroenhancement in open-angle glaucoma: a phase 2 randomized clinical trial. JAMA Ophthalmol. 2022;140(1):11-18. doi: 10.1001/jamaophthalmol.2021.4576